title: Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
abstract: OBJECTIVE
  The objective of this study was to evaluate the potential treatment of atypical and non-atypical endometrial hyperplasia with the levonorgestrel intrauterine system (LNG-IUS).
  
  
  METHODS
  A prospective observational study was undertaken at Queen's Medical Centre's menstrual disorder clinic between 2001 and 2008. Women presenting with abnormal perimenopausal and postmenopausal bleeding, underwent an endometrial biopsy followed by the insertion of a levonorgestrel intrauterine system (LNG-IUS). The study population comprised of 51 patients. The histology of 32 patients (Group A) showed complex hyperplasia without atypia, and in 19 patients (Group B), biopsy revealed atypical endometrial hyperplasia. These patients chose to be managed conservatively with repeat sampling of the endometrium.
  
  
  RESULTS
  Group A: 28 (87.5%) patients out of 32 had regression of their endometrial hyperplasia within the first 12 months of follow-up. Three of the patients achieved regression by 24 months increasing regression rate to 96.8% and the remaining one had a hysterectomy due to a rare side effect. Group B: 16 (84.2%) of 19 patients had regression of the atypical hyperplasia after treatment with the intrauterine system within 12 months of treatment. One patient achieved regression of the hyperplasia by 24 months and two patients went on to have surgical management due to persistent atypia and severe atypia respectively.
  
  
  CONCLUSIONS
  This study contribute further evidence that illustrates that levonorgestrel intrauterine systems have a potential role in patients requiring non-operative management although close follow-up is essential.
authors: Department of Obstetrics and Gynaecology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom. zeinajh@hotmail.com
authors: Zeina J
authors: ZJ
authors: Haoula
authors: Kate F
authors: KF
authors: Walker
authors: Martin C
authors: MC
authors: Powell
mesh_terms: D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D016503:Drug Delivery Systems; D016903:Drug Monitoring; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D016889:Endometrial Neoplasms / Q000209:etiology / Q000517:prevention & control; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008599:Menstruation Disturbances / Q000209:etiology; D008875:Middle Aged; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction
chemical_list: D016588:Anticarcinogenic Agents; D011372:Progestins; D016912:Levonorgestrel